Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for AF Recurrence After Ablation
NCT06433479Completed
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in Atrial fibrillation (AFib) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Atrial fibrillation burden at 3 months. Started Jul 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06433479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433479.